PT91231A - Processo de preparacao de derivados substituidos purinona e de composicoes farmaceuticas que os contem - Google Patents

Processo de preparacao de derivados substituidos purinona e de composicoes farmaceuticas que os contem

Info

Publication number
PT91231A
PT91231A PT91231A PT9123189A PT91231A PT 91231 A PT91231 A PT 91231A PT 91231 A PT91231 A PT 91231A PT 9123189 A PT9123189 A PT 9123189A PT 91231 A PT91231 A PT 91231A
Authority
PT
Portugal
Prior art keywords
4alkyl
hydrogen
pharmaceutical compositions
purinone
preparing
Prior art date
Application number
PT91231A
Other languages
English (en)
Other versions
PT91231B (pt
Inventor
William John Coates
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of PT91231A publication Critical patent/PT91231A/pt
Publication of PT91231B publication Critical patent/PT91231B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT91231A 1988-07-25 1989-07-20 Processo de preparacao de derivados substituidos purinona e de composicoes farmaceuticas que os contem PT91231B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888817651A GB8817651D0 (en) 1988-07-25 1988-07-25 Chemical compounds

Publications (2)

Publication Number Publication Date
PT91231A true PT91231A (pt) 1990-02-08
PT91231B PT91231B (pt) 1995-03-01

Family

ID=10641046

Family Applications (1)

Application Number Title Priority Date Filing Date
PT91231A PT91231B (pt) 1988-07-25 1989-07-20 Processo de preparacao de derivados substituidos purinona e de composicoes farmaceuticas que os contem

Country Status (10)

Country Link
US (1) US5073559A (pt)
EP (1) EP0352960B1 (pt)
JP (1) JPH0288577A (pt)
AT (1) ATE113284T1 (pt)
AU (1) AU613503B2 (pt)
DE (1) DE68919010T2 (pt)
DK (1) DK363689A (pt)
GB (1) GB8817651D0 (pt)
PT (1) PT91231B (pt)
ZA (1) ZA895613B (pt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) * 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
FI951367A7 (fi) * 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
DE19501480A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
CA2270118A1 (en) * 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
DE19702785A1 (de) * 1997-01-27 1998-07-30 Bayer Ag Neue cyclische Harnstoffderivate
CA2288910C (en) * 1997-04-25 2003-06-24 Pfizer Inc. Pyrazolopyrimidinones for sexual dysfunction
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
HU227841B1 (en) 1997-11-12 2012-05-02 Bayer Pharma AG 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
ES2203078T3 (es) 1998-04-20 2004-04-01 Pfizer Inc. Parazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
WO1999062905A1 (en) * 1998-06-03 1999-12-09 Almirall Prodesfarma, S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
HK1049834A1 (zh) 1999-10-11 2003-05-30 辉瑞大药厂 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
BR0207302A (pt) * 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
GB0106661D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
AU2002314044B2 (en) * 2001-05-09 2006-09-21 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
CN100415747C (zh) * 2002-08-08 2008-09-03 记忆药物公司 磷酸二酯酶4抑制剂
US7332486B2 (en) * 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
AU2003282510A1 (en) * 2002-10-11 2004-05-04 Bristol-Myers Squibb Company Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
CN101152185B (zh) * 2003-06-06 2010-12-08 阿里克斯股份公司 杂环化合物作为scce抑制剂的用途
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
CA2623657A1 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2010532319A (ja) * 2007-06-13 2010-10-07 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 聴覚障害の処置用のｐｄｅ阻害剤
WO2011081915A2 (en) * 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
CN104710323B (zh) * 2013-12-11 2018-05-15 中国疾病预防控制中心寄生虫病预防控制所 具有杀螺活性的水杨酰胺酯类化合物及其制备和用途
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
ES2058527T3 (es) * 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators

Also Published As

Publication number Publication date
ATE113284T1 (de) 1994-11-15
DK363689D0 (da) 1989-07-21
US5073559A (en) 1991-12-17
JPH0288577A (ja) 1990-03-28
AU3821089A (en) 1990-01-25
DK363689A (da) 1990-01-26
DE68919010T2 (de) 1995-04-06
DE68919010D1 (de) 1994-12-01
GB8817651D0 (en) 1988-09-01
ZA895613B (en) 1990-05-30
AU613503B2 (en) 1991-08-01
EP0352960A3 (en) 1991-11-06
EP0352960B1 (en) 1994-10-26
PT91231B (pt) 1995-03-01
EP0352960A2 (en) 1990-01-31

Similar Documents

Publication Publication Date Title
ATE113284T1 (de) Purinverbindungen, verfahren zu ihrer herstellung und pharmazeutische präparate.
PT92437A (pt) Processo de preparacao de derivados da quinazolinona, dos seus intermediarios e de composicoes farmaceuticas que os contem
PT92806A (pt) Processo para a preparacao de derivados de 2-amino-pirimidinona e de composicoes farmaceuticas que os contem
PT89047A (pt) Processo para a preparacao de derivados de piridazinamina
PT96145A (pt) Processo para a preparacao de novos derivados de aminoacidos e de composicoes farmaceuticas que os contem
PT93531A (pt) Processo para a preparacao de derivados de n-(3-hidroxi-4-piperidinil)(dihidrobenzofurano,dihidro-2h-benzopirano ou dihidrobenzodioxin)carboxamidas e de composicoes farmaceuticas que os contem
PT89110A (pt) Processo de preparacao de derivados da quinazolina e de composicoes farmaceuticas que os contem
PT91931A (pt) Processo de preparacao de derivados de acido fenilalcanoico e de composicoes farmaceuticas que os contem
PT92935A (pt) Processo para a preparacao de um composto de pirazolo-piridina e de composicoes farmaceuticas que o contem
ES2082805T3 (es) Derivados de tiazol, procedimientos para su produccion y composiciones farmaceuticas que comprenden los mismos.
PT83647B (pt) Processo para a preparacao de novos derivados de benzimidazole com actividade farmacologica e de composicoes farmaceuticas que os contem
PT90478A (pt) Processo para a preparacao de derivados da purina e de composicoes farmaceuticas que os contem
PT89875A (pt) Processo para a preparacao de 4-(4-fenil-1-piperazinil)fenois, inibidores da 5-lipoxigenase, e de composicoes farmaceuticas que os contem
PT92206A (pt) Processo para a preparacao de derivados de 3-piperidinil-1,2-benzizoxazois e de composicoes farmaceuticas que os contem
MX9203550A (es) Derivados de 4-aminoquinolina y su uso como medicamentos.
PT82097B (pt) Processo para a preparacao de derivados de labdano e de composicoes farmaceuticas que os contem
PT91364A (pt) Processo para a preparacao de derivados de 3-piperazinil-benzazol e de composicoes farmaceuticas que os contem
PT90034A (pt) Processo para a preparacao de tetra-hidroimidazo-{1,4}benzodiazepina-2-onas
PT89788A (pt) Processo de preparacao de derivados da quinolina substituidas e de composicoes farmaceuticas que os contem
PT90351A (pt) Processo de preparacao de derivados da fenilpiridona e de composicoes farmaceuticas que os contem
PT87990A (pt) Processo para a preparacao de n-(3-hidroxi-4-piperidinil)benzamidas e de composicoes farmaceuticas que as contem
ATE91682T1 (de) Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung.
PT94034A (pt) Processo para a preparacao de eteres (tio) morfolinilo e piperazinilo-alquilfenolico anti-rinovirais
ES537205A0 (es) Procedimiento para preparar derivados de purina
FI905788A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 6-aryyli-5,6-dihydroimidatso/2,1-b/tiatsolijohdannaisten valmistamiseksi

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19940817

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19960229